SBC vs. PGNY, GRAL, NHC, TDOC, AHCO, VRDN, CDNA, PNTG, AVAH, and AGL
Should you be buying SBC Medical Group stock or one of its competitors? The main competitors of SBC Medical Group include Progyny (PGNY), GRAIL (GRAL), National HealthCare (NHC), Teladoc Health (TDOC), AdaptHealth (AHCO), Viridian Therapeutics (VRDN), CareDx (CDNA), The Pennant Group (PNTG), Aveanna Healthcare (AVAH), and Agilon Health (AGL). These companies are all part of the "healthcare" industry.
SBC Medical Group vs. Its Competitors
Progyny (NASDAQ:PGNY) and SBC Medical Group (NASDAQ:SBC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.
94.9% of Progyny shares are owned by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are owned by institutional investors. 9.4% of Progyny shares are owned by company insiders. Comparatively, 89.5% of SBC Medical Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Progyny had 1 more articles in the media than SBC Medical Group. MarketBeat recorded 3 mentions for Progyny and 2 mentions for SBC Medical Group. SBC Medical Group's average media sentiment score of 0.32 beat Progyny's score of 0.10 indicating that SBC Medical Group is being referred to more favorably in the news media.
Progyny has higher revenue and earnings than SBC Medical Group.
Progyny currently has a consensus price target of $23.45, indicating a potential upside of 9.35%. Given Progyny's stronger consensus rating and higher probable upside, equities research analysts clearly believe Progyny is more favorable than SBC Medical Group.
Progyny has a net margin of 4.33% compared to SBC Medical Group's net margin of 0.00%. SBC Medical Group's return on equity of 26.72% beat Progyny's return on equity.
Progyny has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, SBC Medical Group has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.
Summary
Progyny beats SBC Medical Group on 9 of the 14 factors compared between the two stocks.
Get SBC Medical Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
SBC Medical Group Competitors List
Related Companies and Tools
This page (NASDAQ:SBC) was last updated on 7/7/2025 by MarketBeat.com Staff